3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory and Allergic Conditions
Financed by: European Union
Programme: IMI2-2018-14-01 – Targeted immune intervention for the management of non-response and relapse
Grant Agreement ID: 831434
Rol in the project: Partner
Duration: September 2019 to August 2026
Contact: Gómez Huelgas, Ricardo
Implementation centre: University Regional Hospital of Málaga
Research group of IBIMA involved: Diabetes, Obesity and other Vascular Risk Factors. Systemic Autoimmune Diseases
ABSTRACT
The identification of the molecular mechanisms that can positively or negatively influence a patient’s response to medical treatment is a key issue among health practitioners. A study promoted by 3TR, a consortium of university institutions, SMEs and leading pharmaceutical companies, will address this issue. This EU-funded project will apply bioinformatics and control methods to collect and analyse data from blood, tissues and other fluids during the entire treatment process. It will create a centralised data platform for better management and implement an inclusive molecular and clinical picture of patients experiencing similar diseases. The project intends to explain the role that our microbiome, genetics and regulatory genomics play during treatment.
Partners
-
-
- THE UN IVERSITY OF MANCHESTER
- CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
- UNIVERSITY OF LEICESTER
- EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
- FUNDACIO CENTRE DE REGULACIO GENOMICA
- EUROPEAN RESPIRATORY SOCIETY
- FONDAZIONE IRCCS CA’ GRANDA – OSPEDALE
- MAGGIORE POLICLINICO
- ACADEMISCH MEDISCH CENTRUM BIJ DE
- UNIVERSITEIT VAN AMSTERDAM
- ACADEMISCH ZIEKENHUIS GRONINGEN
- ALACRIS THERANOSTICS GMBH
- ATRYS HEALTH, SA,
- AZIENDA OSPEDALE UNIVERSITA PADOVA
- AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER,
- UNIVERSITEIT GENT
- REGION HOVEDSTADEN
- CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE
- NANCY
- UNIVERSITY OF GLASGOW
- CHARITE – UNIVERSITAETSMEDIZIN BERLIN
- AGENCIA ESTATAL CONSEJO SUPERIOR
- DEINVESTIGACIONES CIENTIFICAS
- CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES
- AUGUST PI I SUNYER
- CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.
- Deutsches Rheuma-Forschungszentrum Berlin
- EUROPEAN FEDERATION OF ASTHMA &ALLERGY
- ASSOCIATIONS IDEELL FORENING
- EUROPEAN LUNG FOUNDATION
- GENOS DOO ZA VJESTACENJE I ANALIZU
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND
- MEDICINE
- INSTITUT NATIONAL DE LA SANTE ET DE LA
- RECHERCHE MEDICALE
- INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO
- ANTUNES
- KAROLINSKA INSTITUTET
- LUPUS EUROPE
-
-
-
- PHILIPPS UNIVERSITAET MARBURG
- QUEEN MARY UNIVERSITY OF LONDON
- SERVICIO ANDALUZ DE SALUD
- SERVICIO MADRILENO DE SALUD
- SIP SERVICE S.R.L.
- SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE
- STICHTING VUMC
- TECHNISCHE UNIVERSITAET DRESDEN
- THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
- THE QUEEN’S UNIVERSITY OF BELFAST
- UNIVERSITA DEGLI STUDI DI CATANIA
- UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
- UNIVERSITA DEGLI STUDI DI CAGLIARI
- UNIVERSITA DEGLI STUDI DI GENOVA
- UNIVERSITA DI PISA,
- UNIVERSITAT BASEL
- CLINIQUES UNIVERSITAIRES SAINT-LUC
- UNIVERSITE DE BRETAGNE OCCIDENTALE
- UNIVERSITEIT HASSELT
- UNIVERSITETET I BERGEN
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND DUBLIN
- UNIVERSITY COLLEGE LONDON
- KATHOLIEKE UNIVERSITEIT LEUVEN
- UNIVERSITY OF SOUTHAMPTON
- UNIVERSYTET MEDYCZNY W LODZI.
- VIB VZW
- SANOFI-AVENTIS DEUTSCHLAND GMBH
- JANSSEN PHARMACEUTICA NV
- TAKEDA DEVELOPMENT CENTRE EUROPE LTD
- ASTRAZENECA AB
- GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
- NOVARTIS PHARMA AG
- PFIZER LIMITED
- F. HOFFMANN-LA ROCHE AG
- MEDIZINISCHE HOCHSCHULE HANNOVER
- OREBRO UNIVERSITY
- OWLSTONE MEDICAL LIMITED
-